阿哌沙班与阿司匹林颅内出血风险的荟萃分析
汇总分析显示阿哌沙班组颅内出血相对风险为0.67(95%CI 0.43-1.08;P=0.10),出血性卒中相对风险为0.72(95%CI 0.39-1.31;P=0.28),提示阿哌沙班颅内出血风险与阿司匹林相当甚至可能更优。
要点
- 阿哌沙班 versus 阿司匹林颅内出血相对风险0.67(95%CI 0.43-1.08),无统计学显著差异。
- 出血性卒中相对风险0.72(95%CI 0.39-1.31;P=0.28),敏感性分析结果一致。
- 因担忧颅内出血而优先选用阿司匹林的临床实践值得重新审视。
核心结论
- 在缺血性卒中预防的随机对照试验中,阿哌沙班颅内出血风险与阿司匹林相当,甚至可能更优。
研究设计与样本
- 研究为随机对照试验的荟萃分析,检索PubMed、Embase、Cochrane Central Register of Controlled Trials和ClinicalTrials.gov。
主要发现
- 阿哌沙班 versus 阿司匹林颅内出血相对风险为0.67(95%CI 0.43-1.08;P=0.10)。
- 出血性卒中(排除硬膜外和硬膜下血肿)相对风险为0.72(95%CI 0.39-1.31;P=0.28)。
- 采用替代统计估计方法、仅限一级预防试验的敏感性分析结果一致。
临床怎么用
- 对于缺血性卒中预防,因担忧颅内出血而优先选用阿司匹林而非阿哌沙班的临床实践值得重新考虑。
局限性
- 仅纳入3项随机对照试验,颅内出血事件总数74例,事件数较少。
- 原文未报告各试验的具体人群特征、随访时长及给药方案等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oral anticoagulants are superior to antiplatelet agents for preventing cardioembolic stroke but concerns about increased risk of intracranial hemorrhage limit their use. Although rivaroxaban demonstrably increases intracranial bleeding risk compared with aspirin, the comparative risk of intracranial hemorrhage with apixaban versus aspirin remains uncertain. We aimed to clarify this risk through a meta-analysis of randomized controlled trials. METHODS: We searched PubMed, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov for randomized controlled trials comparing apixaban with aspirin for ischemic stroke prevention. Studies were excluded if no intracranial hemorrhage events were reported in either arm. In the primary analysis, we used the Mantel-Haenszel method to meta-analyze the relative risk of intracranial hemorrhage with apixaban versus aspirin therapy. We conducted sensitivity analyses to examine the strength of these findings and to examine the secondary outcome of hemorrhagic stroke (which excludes epidural and subdural hematomas). RESULTS: Three randomized controlled trials met our inclusion criteria, comprising a total of 10 626 patients and 74 incident intracranial hemorrhage events. In the pooled analysis, the relative risk of intracranial hemorrhage with apixaban versus aspirin therapy was 0.67 ([95% CI, 0.43-1.08]; P=0.10). These findings were consistent in sensitivity analyses utilizing alternative statistical estimators, in analyses limited to primary prevention trials, and in analyses utilizing the outcome of hemorrhagic stroke (relative risk, 0.72 [95% CI, 0.39-1.31]; P=0.28). CONCLUSIONS: In randomized controlled trials evaluating ischemic stroke prevention, apixaban demonstrated a safety profile comparable-and potentially superior-to aspirin with respect to intracranial hemorrhage risk. These findings warrant a reconsideration of clinical practices that favor aspirin over apixaban due to concerns about intracranial hemorrhage risk.
引用
- Daghlas I, Lieberman OJ, Suleiman L, et al. Risk of Intracranial Hemorrhage With Apixaban Versus Aspirin Therapy: A Meta-Analysis of Randomized Controlled Trials. Stroke. 2025. PMID: 40464082. doi:10.1161/STROKEAHA.125.051088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。